Rituximab
Rituximab is a biologic medication that works by targeting a protein called CD20 on B-cells, which are a type of white blood cell. By binding to CD20, rituximab destroys these cells or helps the immune system destroy these cells, which can be helpful in treating certain conditions.
Nufactor carries the following rituximab brands:
Brand (Manufacturer)
FDA-approved indication(s) [abbreviated]
Brand (Manufacturer):
- Riabni® (Amgen, Inc.)
www.riabni.com - Rituxan® (Genentech, Inc.)
www.rituxan.com - Ruxience® (Pfizer Labs Division of Pfizer, Inc.)
ruxience.pfizerpro.com - Truxima® (Celltrion, Inc.)
www.truxima.com
FDA-approved indication(s) [abbreviated]:
- Chronic Lymphocytic Leukemia (CLL) in combination with fludarabine and cyclophosphamide
- Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in combination with glucocorticoids
- Mature B-cell Non-Hodgkin’s Lymphoma (NHL) and mature B-cell acute leukemia (B-AL) in combination with chemotherapy
- Non-Hodgkin’s Lymphoma (NHL) alone or in combination with other agents
- Pemphigus Vulgaris (PV)
- Rheumatoid Arthritis (RA) in combination with methotrexate
Last reviewed 01/15/2026
The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.
